Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Recipient : Silo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Silo Pharma Starts Key Safety Study for PTSD Drug SPC-15 at Frontage Labs
Details : The agreement aims for a FDA requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 14, 2025
Lead Product(s) : SPC-15
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Recipient : Silo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Mira Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Mira Pharmaceuticals Reports Preclinical Results for Ketamir-2, Aiming for IND Submission
Details : Ketamir-2, a novel oral ketamine analog, is being evaluated for its potential ultra-rapid antidepressant effects in major depressive disorder with suicidal ideation and treatment-resistant depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Mira Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BAN2401 (lecanemab) is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils, being developed for Alzheimer's disease (AD).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
December 12, 2022